Jin‐Hyoung Kang

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

Glenwood Goss, Chun‐Ming Tsai, Frances A. Shepherd et al. · The Lancet Oncology · 2016 · 643 citations

Medicine, Oncology, Pharmacotherapy +9

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 613 citations · Full text

Medicine, Oncology, Pharmacology +12

Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer

Shunichi Sugawara, J.-S. Lee, Jin‐Hyoung Kang et al. · Annals of Oncology · 2021 · 199 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Fractionated Stereotactic Radiotherapy as Reirradiation for Locally Recurrent Head and Neck Cancer

Kwang-Won Roh, Jisun Jang, Min‐Sik Kim et al. · International Journal of Radiation Oncology*Biology*Physics · 2008 · 179 citations

Medicine, Oncology, Radiation Oncology +11

Expression of Viral MicroRNAs in Epstein-Barr Virus-Associated Gastric Carcinoma

Do Nyun Kim, Hiun‐Suk Chae, Sang Taek Oh et al. · Journal of Virology · 2006 · 167 citations · Full text

Life Sciences, Molecular Biology, Oncology +17